Trial Profile

Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events (IDEAL-Study).

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atazanavir (Primary) ; Ritonavir (Primary) ; Atazanavir/ritonavir; Emtricitabine; Tenofovir disoproxil fumarate
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms IDEAL

Most Recent Events

28 May 2013 NCT reports actual initiation date is 1 Aug 2011.
28 May 2013 Planned End Date changed from 1 Aug 2013 to 1 Oct 2016 as reported by ClinicalTrials.gov.
21 Apr 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2010-022413-26).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com